Investor Relations

2021 vs. 2020

€/ mln

2021

2020

YoY

Sales

82.5

64.1

28.7%

Gross margin

27.8

20.3

7.5

Gross margin

33.6%

31.7%

1.9%

Selling and distribution as percentage of sales

-24.7%

-23.8%

-0.9%

Administrative costs as percentage of sales

-5.6%

-7.0%

1.4%

Other operating expensese as percetage of sales

-0.1%

0.0%

-0.1%

Adj. EBITDA*

2.7

0.6

2.1

Adj. EBITDA margin

3.3%

0.9%

2.3%

EBIT

0.3

(0.8)

1.1

Net result

(0.1)

(1.0)

0.9

*Adjusted to take into account the one-off costs related to the acquisition of AmicaFarmacia and the potential other M&A transactions costs